Skip to main content
. Author manuscript; available in PMC: 2011 Dec 2.
Published in final edited form as: Oncogene. 2011 Jan 24;30(22):2526–2533. doi: 10.1038/onc.2010.624

Figure 3.

Figure 3

The combined effects of ATR and p53 genotype on clonogenic survival after drug treatment. (a) ATR-deficient (ATRS/S) cells expressing mutant p53 (p53-/Sil) or wild type p53 (p53+/Sil) and parental DLD-1 controls (ATR+/+p53-/Sil) were treated with cisplatin at doses ranging from 0-1 μM for 48 h, and then replated in drug-free medium. (b) Cells with the indicated genotypes were treated with a single dose (1 μM) of either cisplatin or hydroxyurea (HU) for 24 and 48 h, respectively. Clonogenic survival was assayed as described in Materials and Methods. Error bars represent SEM